JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
NCT06852391 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2026-01-14
Summary
The Joule MARS study is a single center, randomized, open label clinical trial aiming to explore the metabolic adaptations that occur in response to weight management in adolescents with obesity. Behavioural lifestyle intervention with and without a pharmacological intervention - semaglutide- will be studied. Study participants will be randomized to one of two groups. Group A will follow a behavioral lifestyle program (BLP) alone for 6 months, followed by BLP and treatment with semaglutide for six months. Group B will be enrolled in BLP and semaglutide from baseline to 6 months. The primary research question will assess, in youth aged 12-17 years diagnosed with obesity and enrolled in a weight management program, if the implementation of a BLP together with semaglutide, compared to the implementation of BLP alone for 6 months leads to less adaptive thermogenesis.
Conditions
- Obesity (Disorder)
Interventions
- DRUG
-
Semaglutide Pen Injector
Semaglutide will be delivered by a subcutaneous injection using an injectable pen once weekly. Semaglutide is formulated with 5 approved doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). Treatment will commence with the lowest dose and will be increased every 4 weeks to the maximum tolerable dose where they will remain for the remainder of the treatment. Participants who are taking the drug will have monthly visits to assess any adverse events, dose titration and drug adherence.
- BEHAVIORAL
-
Behavioural Lifestyle Program (BLP)
The BLP will be delivered by the Growing Healthy Weight Management (GHWM) pediatric program at McMaster Children's Hospital. GHWM is a family-based program addressing health behaviours (nutritional pattern and eating behaviours, physical activity, sedentary time and sleep) and physical and mental health issues. In Year 1, the program typically includes 2 group sessions and monthly individualized sessions with the participant and their family. The interdisciplinary weight management team is comprised of a registered dietician, exercise physiologist, kinesiologist, social worker and/or psychologist, general pediatrician and pediatric endocrinologists.
Sponsors & Collaborators
-
Canadian Institutes of Health Research (CIHR)
collaborator OTHER_GOV -
Diabetes Canada
collaborator OTHER - lead OTHER
Principal Investigators
-
Katherine M Morrison, MD FRCPC · McMaster University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-18
- Primary Completion
- 2027-12-31
- Completion
- 2027-12-31
Countries
- Canada
Study Locations
More Related Trials
-
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
NCT03611582 ·Status: COMPLETED ·Phase: PHASE3
-
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03693430 ·Status: COMPLETED ·Phase: PHASE3
-
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
NCT05646706 ·Status: COMPLETED ·Phase: PHASE3
-
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
NCT06041217 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
NCT05950516 ·Status: UNKNOWN ·Phase: PHASE3
-
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens
NCT04238962 ·Status: COMPLETED ·Phase: PHASE1
-
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548935 ·Status: COMPLETED ·Phase: PHASE3
-
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
NCT06934655 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Semaglutide in Treatment of Obesity
NCT06604624 ·Status: COMPLETED ·Phase: PHASE3
-
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
NCT05227196 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects
NCT06422624 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
NCT04969939 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
NCT02453711 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss
NCT07280403 ·Status: COMPLETED ·Phase: NA
-
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
NCT04615871 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
NCT02906930 ·Status: COMPLETED ·Phase: PHASE3
-
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
NCT04469855 ·Status: COMPLETED
-
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
NCT07092605 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
NCT06161844 ·Status: COMPLETED ·Phase: PHASE3
-
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
NCT04074161 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277 ·Status: RECRUITING ·Phase: PHASE3
-
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT02692716 ·Status: COMPLETED ·Phase: PHASE3
-
Semaglutide for Post-Smoking Cessation Weight Management
NCT06173778 ·Status: RECRUITING ·Phase: PHASE2
-
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
NCT07055607 ·Status: ENROLLING_BY_INVITATION